The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

Min Pan(St. Jude Children's Research Hospital), Paul Geeleher(St. Jude Children's Research Hospital)
Nature Communications
November 9, 2021
Cited by 90


Related Papers